chrisvoncsefalvay/vaers-outcomes huggingface dataset:
12/26/20: rec?d 1st dose Pfizer Vaccine?shortly afterward, she noticed swelling to the affected area Jan. 2 & 3: didn?t sleep well  Jan. 4: mental fatigued Jan. 7: fever 101.2F, shallow breathing, upper quadrant pain, rash on neck Jan. 8: rash on abdomen; right flank pain?spoke with her Endocrinologist who think reactions are auto-immune related Jan. 15: increased blood pressure?consulted a Cardiologist and was prescribed a medication Jan. 15: had labs drawn?IgG 69 Jan. 28: consulted with a Neurologist who think she may have acute encephalitis related to the vaccine and recommended not to get the 2nd dose
Had seizure at home 9//07, went to ER head CT WNL, no fever, had episode while in ER; sent home to f/u with pediatrician 9/10/07.
Pain to neck, left side of jaw, bilateral knees.  MRI of knees showing significant edema.  Rheumatoid factor and other labs normal.  Diagnosed with Reactive arthritis.  Treatment thus far has included NSAIDs, flexeril, multiple rounds of prednisone, lidocaine injections in both knees, sulfasalazine for 6 months, physical therapy x 1 month, about to start on Enbrel.  Only relief thus far has been from prednisone.
Sometime following vax, the pt developed an episodic stiffness and aching of his fingers. He was seen by his physician. The pt denied swelling, erythema, or constitutional symptoms. The physician stated that the pt's occupation required field work in animal husbandry and a work related cause of his symptoms was possible. The pt was treated with indomethacin, which alleviates the pt's symptoms when they are present.
Initial unsolicited report received from a non-healthcare professional on 11 SEPTEMBER 2015. This case involves a 25 patients (age and gender not reported) who was vaccinated with a (dose not reprioted) intramuscular (dose series not reported) dose of HEPATITIS B (batch number UT443AB, expiry date 30 JUNE 2016, site of administration was not reported) on an unspecified date "multiple". Medical history was not reported. Patient had no other vaccination within four weeks of vaccinations. On an unspecified date, few second "immediately" following the vaccination patients had black dot at the injection site. It was also reported that, patients had no bleeding while doing the injection. BD safety needle with a 25 gauge 1 inch needed was  used for vaccination. Patient had no laboratory investigation done and corrective treatment was not reported. On an unspecified date, patient had recovered. List of documents held by sender: none.
Extreme and uncontrollable coughing (this started about 2 hours and 15 minutes after administration of vaccine), wheezing, tachycardia, sweating, swelling of the uvula and back of throat.  An insurance nurse line was called and the nurse instructed us to call 911.  My husband took me to the ER at the closest hospital.  I was there for about 3 hours and received oxygen, an epi pen, steroids, and breathing treatments.
Pain, redness, swelling at injection site. Overall body aches, shivering, fever, and nausea. Still ongoing 24 hours post injection and not letting up yet.
got the worst flu; Initial information received on 22-Nov-2020 regarding an unsolicited valid non-serious case from a patient.  This case involves a patient of unknown demographics who got the worst flu (influenza), while the patient received vaccine influenza vaccine.  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medication was not reported.  On an unknown date, the patient received a dose of suspect influenza vaccine produced by unknown manufacturer (lot number and expiration date not reported) via unknown route in unknown administration site for prophylaxis vaccination.   On an unknown date, (latency unknown) after the administration of suspect vaccine therapy, patient got the worst flu (influenza) ever in the life.  No laboratory data was provided.   It was not reported if the patient received a corrective treatment.  At the time of report, the outcome was unknown for the event.     There will be no information available on the batch number for this case.
8 DAYS AFTER RECEIVING VACCINE (APRIL 16TH @ 2:00 PM) - WAS AT ARCADE WITH CHILD WHEN I FELT LIKE I WAS HAVING A HEART ATTACK.  THE CHEST PAIN TRAVELED UP TO MY NECK AND JAW, STOPPING JUST BELOW MY EARS.  ARMS FELT HEAVY AND ALMOST USELESS (NOT NUMB). PAIN WAS AT A 10 - SENT ME TO THE GROUND, WHERE I STAYED FOR ABOUT 5 MINUTES UNTIL I WAS ABLE TO GET UP.  DROVE HOME, CONTINUED TO HAVE CHEST PAIN, AROUND PAIN LEVEL 5. AT 5:00 PM IT HAPPENED AGAIN - THOUGHT I WAS HAVING A HEART ATTACK.  INTENSE PAIN LASTED 15 MINUTES.  WENT TO E.R. - GOT CHEST XRAYS, CT SCAN, BLOOD WORK.  NO EVIDENCE OF HEART ATTACK OR BLOOD CLOTS FOUND.  CHEST PAIN HAS STAYED AT ABOUT A 5 EVER SINCE THE ORIGINAL EVENT ON THE 16TH.   APRIL 25TH A RASH
Information has been received from a registered nurse concerning a male patient who on an unspecified date was vaccinated with a second dose of VARIVAX (Merck) (Lot number not provided). The nurse reported that after 2 weeks after being vaccinated the patient came down with the chickenpox from head to toe. At the time of the report the patient's outcome was unknown. It was unspecified if the patient sought medical attention. Follow-up information has been received from the registered nurse concerning the 29-year-old male patient with no known drug allergies and no illness at the time of vaccination who on 06-MAY-2010 at approximately 14:00 was vaccinated subcutaneously into left side with the second dose (the number of previous dose was reported maybe one) of VARIVAX (Merck) (LOT# 665193/1049Y). The nurse reported that after 2 weeks after being vaccinated, on 20-MAY-2010 at 10:30 AM the patient experienced full body rash (described as red with blisters), malaise and low grade fever. The patient called this Primary Care Provider (PCP) who instructed him to stay at home and use calamine lotion. He was not seen by the physician. On 27-MAY-2010, all lesions scabbed and the patient recovered. Follow-up information indicated that the registered nurse sent the report to us on 28-MAY-2010 and were received it on 02-JUN-2010. No further information is available.
approximately 10 minutes after injection developed numbness and mainly tingling sensation above Left deltoid, left scapula area , up left side of neck, left side of face and bottom lip. The symptoms are continuing . tingling sensation also left hand and arm.down to finger tips.Also pain in the back of head left side only. The symptoms have continue after 24 hours. MD contacted. Following up with allergy soon.
The next morning I started getting hives. The first few  weeks they were unbearable. As time goes on they are slowing down, but 4 months later still getting them
LOST HIS VOICE; COUGHING; EXTREMELY SICK; A spontaneous report has been received from a consumer concerning a male patient (age not provided) of Unknown ethnic origin.    No medical history was reported.     No concomitant products were reported.    On an unknown date, patient received Flumist (influenza virus vaccine live, intranasal) once/single administration, via nasal route.     It was reported that reporter's son got this one time ended up extremely sick (preferred term: Malaise),  coughing (preferred term: Cough) and lost his voice (preferred term: Aphonia) took him to the doctor they said it was a reaction to the mist. He gets the shot as they said the flumist has a live virus and thats likely what he reacted to. Shots don't bother him but he was terrified of the mist now.    The outcome of the events of lost his voice, extremely sick and coughing was unknown.     The event lost his voice was considered serious due to important medical event by the company physician. The events extremely sick and coughing were considered non-serious by the company physician.     The reporter considered the events coughing, lost his voice and extremely sick as related to treatment with Flumist.; Sender's Comments: Aphonia is not listed in the company core data sheet of Quadrivalent live attenuated influenza vaccine (Q/LAIV). Reported cough could be risk factor to the event. Due to limited information on relevant medical history ,concurrent conditions, event onset date and outcome, circumstance leading to the event, concomitant medications ,detailed etiological and diagnostic workup , it is not possible to make a conclusive assessment of the causal relationship of event with suspect drug.
Patient states that about 2-3 weeks post vaccination he experienced chest pain, sob, and dizziness. Patient had a hard time getting in with PCP and saw a cardiologist in 10/2021. Patient presents today with no symptoms.
Initial spontaneous report received on 07 November 2014 from a physician who is the patient's parent. An 8 year old male patient with a history of seasonal allergies and allergy to dogs and cats was vaccinated intramuscularly in October 2013 with INFLUENZA QUADRIVAL, batch and site not reported. At an unspecified time the patient began having symptoms at the injection site of swelling; skin was thick, indurated and hot to touch. He was seen by a physician and was prescribed antibiotics. An x-ray on an unspecified date showed fluid and edema at the injection site. The symptoms progressed and in 2-3 days the swelling was over the elbow. The entire arm became swollen from his shoulder to wrist. The patient was hospitalized on an unspecified date for approximately 4 days. On 06 November 2014, the patient received a half dose of INFLUENZA QUADRIVAL, batch, route and site of administration were not reported and the same symptoms occurred, but not as pronounced. The swelling at the injection site occurred within 2 hours of vaccination. The patient's pediatrician contact information and hospital information for 2013 was provided. The patient received FLUMIST, in 2011 and 2012 without a reaction. The patient outcome is not recovered. Documents held by sender: None.
Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023; No adverse event; She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated), PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023) and NO ADVERSE EVENT (No adverse event) in a 35-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 060B22A) for COVID-19 prophylaxis.     It was unknown if patient had ever been diagnosed with/ tested positive for COVID-19.     On 15-Mar-2023, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 15-Mar-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated), PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (She had expired vaccine that was administered on March 15,2023 there was between 75 and 125 people that was vaccinated) and PRODUCT STORAGE ERROR (Expiration date was 26FEB2023 and date the vial was initially stored in the refrigerator on 14MAR2023).    No relevant concomitant medications were reported. It was also reported that there was potentially a second lot number that was expired on 28 Feb 2023 and was administered to patients on 3 Mar 2023, but HCP did not have any details on this event at this time.  Vial size was reported as 10 dose vial. The vial haven't undergone any temperature excursions.  No treatment medication reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-716065 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-716065:Master case
Covid arm. A week after shot a warm red circle around the shot site developed. It was around 2 inches in diameter and itched. It lasted for 3 days and disappeared.
No additional AE reported; HCP reported that a dose of PROQUAD was administered to a adult patient. No additional AE reported. No PQC reported. No further information was provided.; This spontaneous report was received from a medical assistant, referring to a 33-year-old female patient. The patient's pertinent medical history, concomitant medications, previous drug reactions, or allergies were not reported.  On 24-MAR-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD), at a dose of 0.5 millilite (ml) (stength, vaccination scheme, anatomical site of vaccination and route of administration was not reported; lot number W004694, expiration date was reported and validated as 08-AUG-2023) as prophylaxis (product administered to patient of inappropriate age). No additional adverse event reported.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 43-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 12Apr2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 17May2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 30Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Multiple sclerosis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (28Jun2022) Negative; (04Jul2022) Positive; (28Jun2022) Negative; (30Jun2022) Negative; (Jun2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical information: The patient was taking any other medications/products within 2 weeks of starting COVID-19 treatment. The patient was previously received a COVID-19 Vaccine. Rebound of COVID-19 after completing Paxlovid treatment. Patient started Paxlovid on 24Jun2022, after testing positive for COVID-19 . She completed the 5 day treatment on 29Jun2022. She stopped having covid symptoms on 28Jun2022, and tested negative for COVID-19, on 28Jun2022, on both a PCR test and an at home antigen test. She tested negative for COVID-19 on 30Jun, on a PCR test. On 04Jul2022,she began having COVID symptoms again and tested positive on an at home antigen test.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Myalgia Chills Narrative:  Patient called to report symptoms the next day after initial dose. Took OTC Tylenol for muscle pain. Symptoms persisted for a few days before subsiding.  Other Relevant History:
2 hours after immunization - lightheadedness, dizzy, nausea, bilateral leg ache, fatigue, weakness, especially after using legs for some activity.
Increased blood sugar level up to 141 after vaccination; The following information was received from a nurse on 12 Dec 2019.  A 69 year old male received one dose of IXIARO (Japanese encephalitis vaccine, batch number not reported) on 02 Dec 2019.  Co-suspect vaccine included one dose of Hepatitis B vaccine on 04 Dec 2019.   Before vaccination, his fasting blood sugar level was 91 to 96 and after receiving both vaccines the blood sugar increased up to 141.   ---  Follow up information 1 received on 20 Dec 2019.  No reply to follow up request received, hence lost to follow up.; Sender's Comments: Causality assessed as not related, as there is no pathological mechanism known for an inactivated vaccine to cause elevated blood sugar levels. Additionally, the exact time to onset is missing, as well as the description of blood measure method (e.g. fasting) after vaccination.  ---  Causality assessment not changed as no new information was received.
Approximately 5-10 minutes after vaccination was administered, patient began to feel light-headed and cloudy (per description). She proceeded to come back towards the pharmacy when she collapsed to the floor. Was diaphoretic, pulse was difficult to find. EMS was called, went to nearby hospital received fluids. Discharged 10/16/09.
Schedule for dose 2 of Rabavert today, but she missed Day 7. Today is Day 18; Case reference number US-BN-2021-002198 is a spontaneous case report initially received from a nurse via Communications (reference number USBAV21-0420) on 18-Aug-2021, and concerns a female patient in her 30's.  The patient's medical history and concomitant medication details were not provided.  On 30-Jul-2021, the patient was vaccinated with the first dose of RabAvert (inactivated rabies virus vaccine; batch number was not provided), at a dose of 1.0 mL, administered intramuscularly, for pre-exposure prophylaxis due to international travel.    It was reported that the patient was on the schedule for the second dose, on day 7, but missed the second dose (explicitly coded as 'Product dose omission'), and had not received it yet as of day 18, which is the time of this report.  At the time of this report, it was unknown whether the patient received the second dose nor if the patient experienced any adverse event.  The reporter assessed the event as non-serious.   No further information was provided.; Reporter's Comments: Product dose omission issue is listed for RabAvert per convention. Reportedly, the patient missed the scheduled second dose on day 7 after first vaccination for pre-exposure prophylaxis, which is consider as product dose omission issue. No information regarding concomitant medication and medical history were provided. No associated adverse event was reported. Reported event is not related to suspect vaccine, but to human action. The case is considered as non-serious.; Sender's Comments: Product dose omission issue is listed for RabAvert per convention. Reportedly, the patient missed the scheduled second dose on day 7 after first vaccination for pre-exposure prophylaxis, which is consider as product dose omission issue. No information regarding concomitant medication and medical history were provided. No associated adverse event was reported. Reported event is not related to suspect vaccine, but to human action. The case is considered as non-serious.
Client received (2) Tdap - 10/19/07 and 7/20/10, (2) MENACTRA - 10/19/07 and 7/20/10. Mom provided imm. record at clinic site, when HD put record into state system - noted above.
patient was administered with half of a dose instead of the full dose of Moderna COVID-19 Vaccine Bivalent; No Adverse Event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (patient was administered with half of a dose instead of the full dose of Moderna COVID-19 Vaccine Bivalent) and NO ADVERSE EVENT (No Adverse Event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced UNDERDOSE (patient was administered with half of a dose instead of the full dose of Moderna COVID-19 Vaccine Bivalent) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, UNDERDOSE (patient was administered with half of a dose instead of the full dose of Moderna COVID-19 Vaccine Bivalent) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessment was provided for UNDERDOSE (patient was administered with half of a dose instead of the full dose of Moderna COVID-19 Vaccine Bivalent).    No concomitant information was reported. Reporter stated that, patient was administered with half of a dose instead of the full dose of Moderna COVID-19 Vaccine Bivalent. It was unknown if patient reported any AEs. No treatment information was reported.   Reporter did not allow further contact
On 22-Jan-2021 at 9:53 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Jan-2021, the patient experienced PAIN IN EXTREMITY (sore arm) and MYALGIA (body aches). At the time of the report, PAIN IN EXTREMITY (sore arm) and MYALGIA (body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
This is a cluster of 9 unidentified patients who experienced similar adverse events following vaccination with INFLUENZA VACCINE. Initial report received from a health care professional on 22 October 2010. A group of 9 unidentified patients (identifiers not provided) received on 16 October 2010 an injection (routes and sites not provided) of INFLUENZA VACCINE, lot numbers not provided. The patients medical histories and concomitant medications were reported as unknown. It was unknown if the patients had any illness at the time of vaccination. On 17 October 2010, the 9 patients reported redness, swelling and non-specific arm stiffness. The FLUZONE was pre-drawn into "disp" syringes the day before. The outcomes were reported as unknown. Follow-up information was received from a health care professional on 13 December 2010. The patient was identified as a 76-year-old female patient who received on 16 October 2010 a left arm (tricep) injection of FLUZONE, lot number U3653AA, a left deltoid injection of ADACEL, lot number C3490AA and a right deltoid injection of PNEUMOVAX, Merck lot number 0882Z. The outcome remained reported as unknown. Documents held by sender: None.
After my 1st vaccine, about 12 to 36 hours later I slowly started noticing rashes and hives on parts of my body. I already had a poison oak rash, so the timeline is a little rough as to when I was sure it wasn't a new poison oak rash (on a new part of my body), and was truly hives or a new rash. Then it became more obvious by 36 plus hours, due to hives on hands, feet, and lower torso/upper thigh areas, and my week-old poison oak rash was getting much better.
Flu like symptoms: body aches, feverish, fatigue, headache evening of the vaccination. Following 2 days milder symptoms mainly body aches and fatigue no fever.